Navigation Links
Angiotech to participate in Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
Date:1/29/2008

VANCOUVER, Jan. 29 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, is scheduled to participate in the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference, which is being held February 5-7 in New York, NY.

Dr. William Hunter, Angiotech's President and Chief Executive Officer, is scheduled to present on Tuesday, February 5, at the Grand Hyatt New York, beginning at approximately 3:20 pm ET. A Question and Answer period will immediately follow the presentation.

A live audio-only webcast will be available to all interested parties on the company's website, http://www.angiotech.com under the Investors section.

About Angiotech

Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech (NASDAQ: ANPI, TSX: ANP), please visit our website at http://www.angiotech.com.

CONTACT: Deirdre Neary, Manager, Investor Relations, Angiotech Pharmaceuticals, Inc., (604) 222-7056, dneary@angio.com


'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Angiotech Pharmaceuticals, Inc. - Notice of Conference Call and Webcast
2. Angiotech and Symphony Medical Announce Licensing Agreement
3. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
4. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
5. Angiotech to participate in RBC 2007 Healthcare Conference
6. Angiotech to participate in Bank of America 2007 Credit Conference
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
9. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
10. Angiotech to participate in UBS Global Life Sciences Conference
11. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... August 20, 2014 Not long ago, ... studies should be performed late in the development cycle ... But current regulatory trends suggest that, like many things ... rise. In recent years, multiple drug sponsors have been ... address specific questions during phase I/II. It’s not only ...
(Date:8/19/2014)... (PRWEB) August 20, 2014 One ... regenerative medicine is an inadequate vascular supply. Nutrient ... and decellularized tissues is critical for successful regeneration ... attempted to mitigate deficiencies in vascularization and promote ... scaffold bioactivity, optimizing scaffold design and architecture, and ...
(Date:8/19/2014)... Research and Markets  has announced the addition of the ... Report" report to their offering. This ... (SOFCs) in US$ Thousands. The report provides separate comprehensive analytics ... Europe , Asia-Pacific , and Rest ... period 2012 through 2020. Market data and analytics are derived ...
(Date:8/19/2014)... In November 2012, the European Union (EU) mandated use ... a new PSUR – responding to the increasing need to ... drug. Adopted in many regions, the main objectives of the ... and critical analysis of new or emerging information on the ... evidence of the potential benefits of a drug; and , ...
Breaking Biology Technology:Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2
... M plus potential annual revenue to ProMetic derived from first ... hyperimmune product - Kedrion ... technology in Kedrion,s ... process, MONTREAL, Feb. 26 /PRNewswire-FirstCall/ - ProMetic Life Sciences Inc.,("ProMetic") (TSX:PLI) announced today ...
... pathogen detection capabilities for air samples using an advanced ... ... Systems Inc.,(MFSI) today announced that it has signed agreements with ... Applera Corporation,business, and Hamilton Sundstrand, a United Technologies (NYSE: ...
... up from $42 ... product sales expected with delivery of ABthrax(TM) to ... - First Albuferon(R) Phase 3 data expected late 2008 -, - Enrollment completed in randomized Phase 2 ... myeloma -, ...
Cached Biology Technology:ProMetic announces signature of definitive license agreement with Kedrion for two hyperimmune products 2ProMetic announces signature of definitive license agreement with Kedrion for two hyperimmune products 3ProMetic announces signature of definitive license agreement with Kedrion for two hyperimmune products 4Microfluidic Systems Announces Agreements With Applied Biosystems and United Technologies' Hamilton Sundstrand Division for Production of Bioagent Autonomous Networked Detector System 2Microfluidic Systems Announces Agreements With Applied Biosystems and United Technologies' Hamilton Sundstrand Division for Production of Bioagent Autonomous Networked Detector System 3Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress 2Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress 3Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress 4Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress 5Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress 6Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress 7Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress 8Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress 9Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress 10Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress 11
(Date:8/20/2014)... Arizona State University, the Wellcome Trust Sanger Institute and ... isolated Mycobacterium pinnipedii from skeletons found in ... pathogen is a relative of the TB bacterium that ... today. These researchers assume that seals carried the pathogens ... sea lions was unexpected" comments Sebastien Gagneux, from the ...
(Date:8/20/2014)... Calif., August 19, 2014 -- Bay Area Lyme Foundation, ... and simple to cure, applauds new research published in ... Ticks and Tick-borne Diseases . The findings ... California are active throughout the year, making the threat ... researchers at California Department of Public Health (CDPH) Vector-borne ...
(Date:8/20/2014)... have suffered concussions ready to return to action? A ... school athletes who head back on the field with ... in their abilities to simultaneously walk and do simple ... in their balance and/or altered walking speed, was found ... had returned to activity in less than a month. ...
Breaking Biology News(10 mins):Lyme disease risk is year-round in Northwest California, according to new study 2Lyme disease risk is year-round in Northwest California, according to new study 3Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3
... research from Rice University, Baylor College of Medicine (BCM) and ... of flow in the small blood vessels of the heart ... and form dangerous blood clots. The scientists were surprised to ... shape for up to five hours before returning to their ...
... Department of Energy,s National Renewable Energy Laboratory (NREL) eases and ... industry: determining cell wall chemistry to find plants with ideal ... thoroughly analyze hundreds of biomass samples a day and give ... pursuing. Analysis of a sample that previously took two weeks ...
... VA As the Colorado River winds through the Colorado ... of sediment. This sediment which once left the river,s ... Colorado "the reddish river" is a vital component to ... of the Hoover and Glen Canyon dams, which trap the ...
Cached Biology News:Stressed proteins can cause blood clots for hours 2Stressed proteins can cause blood clots for hours 3Biomass analysis tool is faster, more precise 2Biomass analysis tool is faster, more precise 3Biomass analysis tool is faster, more precise 4Biomass analysis tool is faster, more precise 5
... Rat Antibody to Human CD66 ... is expressed by human neutrophils and ... carcinoma. Clone YTH71.3 reacts with transfectants ... are CEA subfamily members(2). ...
This STAT antibody sampler pack contains 8 monoclonal ,STAT antibodies....
Request Info...
Invitrogen's Calcium Phosphate Transfection Kit provides high-quality reagents to enable the introduction of DNA into tissue culture cells via calcium phosphate co-precipitation....
Biology Products: